Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voyager-V1 and Cemiplimab in Relapsed/Refractory Peripheral T-cell Lymphoma
NCT06508463Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Jan 2024
- Primary completion
- Dec 2028
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of Voyager-V1 in peripheral T-cell lymphoma (PTCL) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Incidence of adverse events of grade 3 or higher up to 2 years. Started Jan 2024; status: recruiting.
02
Drugs
Voyager-V1
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06508463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06508463.